- Ivosidenib
-
- $66.00 / 5mg
-
2024-11-19
- CAS:1448347-49-6
- Min. Order:
- Purity: 99.7%
- Supply Ability: 10g
- RG120
-
- $1.00 / 1g
-
2019-12-23
- CAS:1448347-49-6
- Min. Order: 1g
- Purity: 99.99%
- Supply Ability: 200kg
Related articles - The synthesis method of Ivosidenib
- Ivosidenib is a first-in-class, oral small molecule, potent and selective inhibitor of mutant isocitrate dehydrogenase 1 (mIDH....
- Dec 28，2023
|
| | Ivosidenib Basic information |
| Product Name: | Ivosidenib | | Synonyms: | RG120;RG120 100MG;(S)-N-((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide;(2S)-1-(4-Cyano-2-pyridinyl)-5-oxo-L-prolyl-2-(2-chlorophenyl)-N-(3,3-difluorocyclobutyl)-N2-(5-fluoro-3-pyridinyl)glycinamide;Glycinamide, 1-(4-cyano-2-pyridinyl)-5-oxo-L-prolyl-2-(2-chlorophenyl)-N-(3,3-difluorocyclobutyl)-N2-(5-fluoro-3-pyridinyl)-, (2S)-;AG120;AG 120;CS-1721;EOS-60845 | | CAS: | 1448347-49-6 | | MF: | C28H22ClF3N6O3 | | MW: | 582.96 | | EINECS: | | | Product Categories: | API | | Mol File: | 1448347-49-6.mol |  |
| | Ivosidenib Chemical Properties |
| Melting point | 151-173°C | | Boiling point | 854.3±65.0 °C(Predicted) | | density | 1.51±0.1 g/cm3(Predicted) | | storage temp. | -20°C Freezer, Under inert atmosphere | | solubility | Chloroform (Slightly), Methanol (Slightly) | | pka | 11.58±0.40(Predicted) | | form | Solid | | color | White to Off-White |
| | Ivosidenib Usage And Synthesis |
| Description | AG-120 is an orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1) that specifically inhibits a mutated form of IDH1 in the cytoplasm, preventing the formation of 2-hydroxyglutarate. AG-120 may induce cellular differentiation as well as inhibit proliferation in IDH1-expressing tumor cells. | | Uses | Ivosidenib is a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers. | | Definition | ChEBI: Ivosidenib is a tertiary carboxamide resulting from the formal condensation of the carboxy group of (2S)-1-(4-cyanopyridin-2-yl)-5-oxopyrrolidine-2-carboxylic acid with the secondary amino group of (2S)-2-(2-chlorophenyl)-N-(3,3-difluorocyclobutyl)-2-[(5-fluoropyridin-3-yl)amino]acetamide. It is approved by the FDA for the treatment of acute myeloid leukemia (AML) in patients with an isocitrate dehydrogenase-1 (IDH1) mutation. It has a role as an antineoplastic agent and an EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor. It is a member of monochlorobenzenes, a cyanopyridine, a member of pyrrolidin-2-ones, an organofluorine compound, a tertiary carboxamide and a secondary carboxamide. | | in vitro | tf-1 cells or primary human aml patient samples expressing mutant idh1 were treated with ag-120, and the results showed that in tf-1 idh1-r132h cells, ag-120 was able to decrease the intracellular 2-hg levels, inhibit growth factor independent proliferation and restore erythropoietin-induced differentiation [1]. | | IC 50 | < 100 nm | | storage | Store at -20°C | | references | [1] erica hansen et al. ag-120, an oral, selective, first-in-class, potent inhibitor of mutant idh1, reduces intracellular 2hg and induces cellular differentiation in tf-1 r132h cells and primary human idh1 mutant aml patient samples treated ex vivo. blood 2014 124:3734.
[2] http://www. aacr.org/newsroom/pages/news-release-detail.aspx itemid=789#.wlauom997iu |
| | Ivosidenib Preparation Products And Raw materials |
|